References
- Kameda T, Dobashi H. Rheumatoid arthritis and malignancy. Nippon Rinsho. 2016;74(6):1017–21.
- Yamashita H, Ueda Y, Ozaki T, Tsuchiya H, Takahashi Y, Kaneko H, et al. Characteristics of 10 patients with paraneoplastic rheumatologic musculoskeletal manifestations. Mod Rheumatol. 2014;24(3):492–8.
- Ungprasert P, Sanguankeo A, Upala S, Knight EL. Risk of malignancy in patients with giant cell arteritis and polymyalgia rheumatica: a systematic review and meta-analysis. Semin Arthritis Rheum. 2014;44(3):366–70.
- Muller S, Hider SL, Belcher J, Helliwell T, Mallen CD. Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Ann Rheum Dis. 2014;73(10):1769–73.
- Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis. 1979;38(5):434–9.
- Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Ann Rheum Dis. 2012;71(4):484–92.
- Dasgupta B, Cimmino MA, Kremers HM, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology Collaborative Initiative. Arthritis Rheum. 2012;64(4):943–54.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010;62(9):2569–81.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis. 2010;69(9):1580–8.
- Matsui K, Nogami M, Hashimoto N, Nishioka A, Sekiguchi M, Azuma N, et al. Clinical outcomes of 79 patients with polymyalgia rheumatica. Rinsho Riumachi. 2016; 28:135–42.
- Naschitz JE, Slobodin G, Yeshurun D, Rozenbaum M, Rosner I. A polymyalgia rheumatica-like syndrome as presentation of metastatic cancer. J Clin Rheumatol. 1996;2(6):305–8.
- Meliconi R, Pulsatelli L, Dolzani P, Boiardi L, Macchioni P, Salvarani C, et al. Vascular endothelial growth factor production in polymyalgia rheumatica. Arthritis Rheum. 2000;43(11):2472–80.
- Karmacharya P, Donato AA, Aryal MR, Ghimire S, Pathak R, Shah K, et al. RS3PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol. 2016;34(3):404–15.
- Arima K, Origuchi T, Tamai M, Iwanaga N, Izumi Y, Huang M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis. 2005;64(11):1653–5.
- Crociani O, Lastraioli E, Boni L, Pillozzi S, Romoli MR, D'Amico M, et al. hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathological correlations and therapeutical implications. Clin Cancer Res. 2014;20(6):1502–12.
- Emamifar A, Hess S, Gerke O, Hermann AP, Laustrup H, Hansen PS, et al. Polymyalgia rheumatica and giant cell arteritis-three challenges-consequences of the vasculitis process, osteoporosis, and malignancy: a prospective cohort study protocol. Medicine (Baltimore). 2017;96(26):e7297.